At a glance
- Originator Shionogi
- Class Antibacterials
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- Discontinued Mycoplasma infections
Most Recent Events
- 30 Jun 1998 Discontinued-Preclinical for Mycoplasma infections in Japan (Unknown route)
- 13 May 1998 Investigation in Mycoplasma infections in Japan (Unknown route)